Recent research has shown surprising health benefits of coffee, including a reduction in AFib frequency and a decrease in the ...

The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

SAN DIEGO, Jan. 6, 2026 /PRNewswire/ — HUYABIO International today announced favorable Phase 1 clinical data for HBI-3000, a novel bioinspired investigational drug with promising antiarrhythmic ...

AP31969 is a novel, first-in-class, oral SK ion channel inhibitor intended for rhythm control of atrial fibrillation and has recently completed Phase 1 in healthy volunteers ...

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

Svennberg E et al. Transforming Atrial Fibrillation Management by Targeting Comorbidities and Reducing Atrial Fibrillation Burden: the 10th AFNET/EHRA Consensus Conference. Europace, 15 Dec 2025. DOI: ...

Key takeawaysAn international panel of more than 80 experts has issued updated guidance to improve care for atrial fibrillation (AF) patients ...

Dr Emma Svennberg, cardiologist in Stockholm and first author of the consensus paper, noted that modern AF care requires a more streamlined and holistic approach. She highlighted the need to address ...

Atrial fibrillation treatments can slow and normalize your heartbeat. AFib triggers can include obesity, diabetes, and excessive alcohol use. Antiarrhythmic drugs are used to help maintain a normal ...